{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:12:50Z","timestamp":1791947570986,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Emicizumab is a bispecific monoclonal antibody that substitutes for the function of missing or deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy of emicizumab have been demonstrated in several clinical trials. Nevertheless, in the first of these, three cases of thrombotic microangiopathy (TMA) occurred in PwHA treated with emicizumab receiving high doses of activated prothrombin complex concentrate (aPCC), a bypassing agent used for treating breakthrough bleeds when FVIII neutralizing antibodies (inhibitors) make FVIII replacement ineffective. The aim of the present work is to offer a method to elucidate the pathophysiological and pharmacological mechanisms involved in this treatment-induced TMA. Systems biology and machine learning-based Therapeutic Performance Mapping System is a validated in silico technology that allowed us to construct models of potential mechanisms behind induced TMA. Two drug combinations were modeled and assessed: emicizumab plus aPCC and emicizumab plus recombinant activated factor VII (another bypassing agent). Our models showed that both combinations were related to activation of the coagulation cascade. However, mechanisms involved mainly in platelet activation and possibly in complement activation were detected only for emicizumab plus aPCC, potentially explaining the occurrence of TMA only in this combination.<\/jats:p>","DOI":"10.1038\/s41598-023-36891-x","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T09:03:35Z","timestamp":1687338215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab"],"prefix":"10.1038","volume":"13","author":[{"given":"Raquel","family":"Valls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Wagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ido","family":"Paz-Priel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Artigas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Jaccard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Coma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"36891_CR1","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s40265-019-01200-2","volume":"79","author":"HA Blair","year":"2019","unstructured":"Blair, H. A. Emicizumab: A review in haemophilia A. Drugs 79, 1697\u20131707 (2019).","journal-title":"Drugs"},{"key":"36891_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava, A. et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 26, 1\u2013158 (2020).","journal-title":"Haemophilia"},{"key":"36891_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.hoc.2019.01.007","volume":"33","author":"MC Pelland-Marcotte","year":"2019","unstructured":"Pelland-Marcotte, M. C. & Carcao, M. D. Hemophilia in a changing treatment landscape. Hematol. Oncol. Clin. N. Am. 33, 409\u2013423 (2019).","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"36891_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/ijlh.12659","volume":"39","author":"JD Lai","year":"2017","unstructured":"Lai, J. D. & Lillicrap, D. Factor VIII inhibitors: Advances in basic and translational science. Int. J. Lab. Hematol. 39, 6\u201313 (2017).","journal-title":"Int. J. Lab. Hematol."},{"key":"36891_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/2040620718785363","volume":"9","author":"S Arshad","year":"2018","unstructured":"Arshad, S., Singh, A., Awasthi, N. P., Kumari, S. & Husain, N. Clinicopathological parameters influencing inhibitor development in patients with hemophilia A receiving on-demand therapy. Ther. Adv. Hematol. 9, 213\u2013226 (2018).","journal-title":"Ther. Adv. Hematol."},{"key":"36891_CR6","unstructured":"Novo Nordisk. NovoSeven\u00ae RT [Package Insert]. https:\/\/www.fda.gov\/media\/70442\/download (Accessed January 2023)."},{"key":"36891_CR7","unstructured":"Baxter, A. G. FEIBA\u00ae [Package Insert]. https:\/\/www.fda.gov\/media\/78852\/download (Accessed January 2023)."},{"key":"36891_CR8","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/j.1538-7836.2012.04793.x","volume":"10","author":"M Hoffman","year":"2012","unstructured":"Hoffman, M. & Dargaud, Y. Mechanisms and monitoring of bypassing agent therapy. J. Thromb. Haemost. 10, 1478\u20131485 (2012).","journal-title":"J. Thromb. Haemost."},{"key":"36891_CR9","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/jth.12987","volume":"13","author":"S Furukawa","year":"2015","unstructured":"Furukawa, S. et al. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry. J. Thromb. Haemost. 13, 1279\u20131284 (2015).","journal-title":"J. Thromb. Haemost."},{"key":"36891_CR10","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/nm.2942","volume":"18","author":"T Kitazawa","year":"2012","unstructured":"Kitazawa, T. et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat. Med. 18, 1570\u20131574 (2012).","journal-title":"Nat. Med."},{"key":"36891_CR11","unstructured":"F. Hoffmann-La Roche Ltd. Hemlibra\u00ae (emicizumab-kxwh) [Package Insert]. United States Prescribing Information (USPI). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761083s011lbl.pdf (Accessed January 2023)."},{"key":"36891_CR12","unstructured":"MASAC Document #258. Recommendation on the Use and Management of Emicizumab\u2010kxwh (Hemlibra\u00ae) for Hemophilia A with and without Inhibitors. https:\/\/www.hemophilia.org\/sites\/default\/files\/document\/files\/258_emicizumab.pdf (Accessed January 2023)."},{"key":"36891_CR13","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1182\/blood.2020009217","volume":"137","author":"MU Callaghan","year":"2021","unstructured":"Callaghan, M. U. et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1\u20134 studies. Blood 137, 2231\u20132242 (2021).","journal-title":"Blood"},{"key":"36891_CR14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg, J. et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N. Engl. J. Med. 377, 809\u2013818 (2017).","journal-title":"N. Engl. J. Med."},{"key":"36891_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/hae.13877","volume":"26","author":"PT Ebbert","year":"2020","unstructured":"Ebbert, P. T., Xavier, F., Seaman, C. D. & Ragni, M. V. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors. Haemophilia 26, 41\u201346 (2020).","journal-title":"Haemophilia"},{"key":"36891_CR16","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1182\/blood-2021-146147","volume":"138","author":"M Howard","year":"2021","unstructured":"Howard, M., McKinley, D., Sanabria, F., Ko, R. H. & Nissen, F. Evaluation of the safety of emicizumab prohylaxis in persons with Hemophilia A: An updated summary of thrombotic events and thrombotic microangiopathies. Blood 138, 3186 (2021).","journal-title":"Blood"},{"key":"36891_CR17","doi-asserted-by":"publisher","first-page":"E153","DOI":"10.1503\/cmaj.160142","volume":"189","author":"DM Arnold","year":"2017","unstructured":"Arnold, D. M., Patriquin, C. J. & Nazy, I. Thrombotic microangiopathies: A general approach to diagnosis and management. CMAJ 189, E153\u2013E159 (2017).","journal-title":"CMAJ"},{"key":"36891_CR18","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.hoc.2017.08.010","volume":"31","author":"S Kappler","year":"2017","unstructured":"Kappler, S., Ronan-Bentle, S. & Graham, A. Thrombotic microangiopathies (TTP, HUS, HELLP). Hematol. Oncol. Clin. N. Am. 31, 1081\u20131103 (2017).","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"36891_CR19","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","volume":"125","author":"ZL Al-Nouri","year":"2015","unstructured":"Al-Nouri, Z. L., Reese, J. A., Terrell, D. R., Vesely, S. K. & George, J. N. Drug-induced thrombotic microangiopathy: A systematic review of published reports. Blood 125, 616\u2013618 (2015).","journal-title":"Blood"},{"key":"36891_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fmed.2020.00212","volume":"22","author":"T Chatzikonstantinou","year":"2020","unstructured":"Chatzikonstantinou, T., Gavriilaki, M., Anagnostopoulos, A. & Gavriilaki, E. An update in drug-induced thrombotic microangiopathy. Front. Med. 22, 212 (2020).","journal-title":"Front. Med."},{"key":"36891_CR21","doi-asserted-by":"publisher","first-page":"e565","DOI":"10.1111\/hae.13091","volume":"22","author":"LA Williams 3rd","year":"2016","unstructured":"Williams, L. A. 3rd. et al. Acquired autoimmune thrombotic thrombocytopenic purpura in a case of severe haemophilia A. Haemophilia 22, e565\u2013e567 (2016).","journal-title":"Haemophilia"},{"key":"36891_CR22","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1111\/jth.14556","volume":"17","author":"M Makris","year":"2019","unstructured":"Makris, M., Iorio, A. & Lenting, P. J. Emicizumab and thrombosis: The story so far. J. Thromb. Haemost. 17, 1269\u20131272 (2019).","journal-title":"J. Thromb. Haemost."},{"key":"36891_CR23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13075-021-02507-w","volume":"23","author":"C Seg\u00fa-Verg\u00e9s","year":"2021","unstructured":"Seg\u00fa-Verg\u00e9s, C. et al. Application of systems biology-based in silico tools to optimize treatment strategy identification in Still\u2019s disease. Arthritis Res. Ther. 23, 126 (2021).","journal-title":"Arthritis Res. Ther."},{"key":"36891_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.18632\/oncotarget.27875","volume":"12","author":"E Carcereny","year":"2021","unstructured":"Carcereny, E. et al. Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach. Oncotarget 12, 316\u2013332 (2021).","journal-title":"Oncotarget"},{"key":"36891_CR25","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/s41598-018-19767-3","volume":"8","author":"D Romeo-Guitart","year":"2018","unstructured":"Romeo-Guitart, D. et al. Neuroprotective drug for nerve trauma revealed using artificial intelligence. Sci. Rep. 8, 1879 (2018).","journal-title":"Sci. Rep."},{"key":"36891_CR26","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jacbts.2019.07.010","volume":"4","author":"O Iborra-Egea","year":"2019","unstructured":"Iborra-Egea, O. et al. Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes. JACC Basic Transl. Sci. 4, 831\u2013840 (2019).","journal-title":"JACC Basic Transl. Sci."},{"key":"36891_CR27","doi-asserted-by":"publisher","first-page":"e0228926","DOI":"10.1371\/journal.pone.0228926","volume":"15","author":"G Jorba","year":"2020","unstructured":"Jorba, G. et al. In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan. PLoS ONE 15, e0228926. https:\/\/doi.org\/10.1371\/journal.pone.0228926 (2020).","journal-title":"PLoS ONE"},{"key":"36891_CR28","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart, D. S. et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074\u2013D1082 (2018).","journal-title":"Nucleic Acids Res."},{"key":"36891_CR29","doi-asserted-by":"publisher","first-page":"D380","DOI":"10.1093\/nar\/gkv1277","volume":"44","author":"D Szklarczyk","year":"2016","unstructured":"Szklarczyk, D. et al. STITCH 5: Augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 44, D380\u2013D384 (2016).","journal-title":"Nucleic Acids Res."},{"key":"36891_CR30","doi-asserted-by":"publisher","first-page":"D1113","DOI":"10.1093\/nar\/gkr912","volume":"40","author":"N Hecker","year":"2012","unstructured":"Hecker, N. et al. SuperTarget goes quantitative: Update on drug-target interactions. Nucleic Acids Res. 40, D1113\u2013D1117 (2012).","journal-title":"Nucleic Acids Res."},{"key":"36891_CR31","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","volume":"127","author":"N Uchida","year":"2016","unstructured":"Uchida, N. et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 127, 1633\u20131641 (2016).","journal-title":"Blood"},{"key":"36891_CR32","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","volume":"374","author":"M Shima","year":"2016","unstructured":"Shima, M. et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N. Engl. J. Med. 374, 2044\u20132053 (2016).","journal-title":"N. Engl. J. Med."},{"key":"36891_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/hae.14205","volume":"27","author":"M Shima","year":"2021","unstructured":"Shima, M. et al. Long-term safety and efficacy of emicizumab for up to 5.8 years and patients\u2019 perceptions of symptoms and daily life: A phase 1\/2 study in patients with severe haemophilia A. Haemophilia 27, 81\u201389 (2021).","journal-title":"Haemophilia"},{"key":"36891_CR34","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.2019001869","volume":"134","author":"G Young","year":"2019","unstructured":"Young, G. et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 134, 2127\u20132138 (2019).","journal-title":"Blood"},{"key":"36891_CR35","unstructured":"CIOMS. Guidelines for Preparing Core Clinical-Safety Information on Drugs. Second Edition. Report of CIOMS Working Groups III and V Citation in Media. https:\/\/cioms.ch\/publications\/product\/guidelines-preparing-core-clinical-safety-information-drugs-second-edition-report-cioms-working-groups-iii-v\/#description (Accessed January 2023)."},{"key":"36891_CR36","first-page":"757","volume":"12","author":"MM Nowotka","year":"2017","unstructured":"Nowotka, M. M. et al. Using ChEMBL web services for building applications and data processing workflows relevant to drug discovery. Expert Opin. Drug Discov. 12, 757\u2013767 (2017).","journal-title":"Expert Opin. Drug Discov."},{"key":"36891_CR37","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"key":"36891_CR38","doi-asserted-by":"publisher","first-page":"e0147626","DOI":"10.1371\/journal.pone.0147626","volume":"11","author":"M Herrando-Grabulosa","year":"2016","unstructured":"Herrando-Grabulosa, M. et al. Novel neuroprotective multicomponent therapy for amyotrophic lateral sclerosis designed by networked systems. PLoS ONE 11, e0147626 (2016).","journal-title":"PLoS ONE"},{"key":"36891_CR39","doi-asserted-by":"publisher","first-page":"e0240149","DOI":"10.1371\/journal.pone.0240149","volume":"15","author":"L Artigas","year":"2020","unstructured":"Artigas, L. et al. In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. PLoS ONE 15, e0240149 (2020).","journal-title":"PLoS ONE"},{"key":"36891_CR40","doi-asserted-by":"crossref","unstructured":"Ellson, J. et al. North and Gordon Woodhull. Graphviz\u2014Open source graph drawing tools. In\u00a0International Symposium Graph Drawing and Network Visualization\u00a0(2001).","DOI":"10.1007\/3-540-45848-4_57"},{"key":"36891_CR41","unstructured":"Adobe Inc. Adobe Photoshop. https:\/\/www.adobe.com\/products\/photoshop.html (2013). (Accessed January 2023)."},{"key":"36891_CR42","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1111\/jth.14491","volume":"17","author":"GG Levy","year":"2019","unstructured":"Levy, G. G. et al. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program. J. Thromb. Haemost. 17, 1470\u20131477 (2019).","journal-title":"J. Thromb. Haemost."},{"key":"36891_CR43","doi-asserted-by":"publisher","first-page":"e28934","DOI":"10.1002\/pbc.28934","volume":"68","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y., Weyand, A. C. & Shavit, J. A. Novel treatments for hemophilia through rebalancing of the coagulation cascade. Pediatr. Blood Cancer 68, e28934 (2021).","journal-title":"Pediatr. Blood Cancer"},{"key":"36891_CR44","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1111\/jth.14203","volume":"16","author":"R Hartmann","year":"2018","unstructured":"Hartmann, R., Feenstra, T., Valentino, L., Dockal, M. & Scheiflinger, F. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. J. Thromb. Haemost. 16, 1580\u20131591 (2018).","journal-title":"J. Thromb. Haemost."},{"key":"36891_CR45","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jtha.2023.03.007","volume":"6","author":"J Lund","year":"2023","unstructured":"Lund, J. et al. In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays. J. Thromb. Haemost. 6, 1493\u20131502 (2023).","journal-title":"J. Thromb. Haemost."},{"key":"36891_CR46","doi-asserted-by":"publisher","first-page":"e929616","DOI":"10.12659\/AJCR.929616","volume":"22","author":"HHC Tsai","year":"2021","unstructured":"Tsai, H. H. C., Moyers, J. T., Moore, C. J. & Thinn, M. Activated prothrombin complex concentrate-induced atypical hemolytic uremic syndrome treated with eculizumab. Am. J. Case Rep. 22, e929616 (2021).","journal-title":"Am. J. Case Rep."},{"key":"36891_CR47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bpc.2004.07.011","volume":"112","author":"HA Scheraga","year":"2004","unstructured":"Scheraga, H. A. The thrombin-fibrinogen interaction. Biophys. Chem. 112, 117\u2013130 (2004).","journal-title":"Biophys. Chem."},{"key":"36891_CR48","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/apha.12007","volume":"206","author":"P Hillmeister","year":"2012","unstructured":"Hillmeister, P. & Persson, P. B. The Kallikrein\u2013Kinin system. Acta Physiol. (Oxf.) 206, 215\u2013219 (2012).","journal-title":"Acta Physiol. (Oxf.)"},{"key":"36891_CR49","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1182\/blood-2011-06-363648","volume":"118","author":"F Liu","year":"2011","unstructured":"Liu, F., Huang, J. & Sadler, J. E. Shiga toxin (Stx)1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways. Blood 118, 3392\u20133398 (2011).","journal-title":"Blood"},{"key":"36891_CR50","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jbior.2015.06.001","volume":"59","author":"GF Guidetti","year":"2015","unstructured":"Guidetti, G. F., Canobbio, I. & Torti, M. PI3K\/Akt in platelet integrin signaling and implications in thrombosis. Adv. Biol. Regul. 59, 36\u201352 (2015).","journal-title":"Adv. Biol. Regul."},{"key":"36891_CR51","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1182\/blood-2014-02-557975","volume":"124","author":"G Haddad","year":"2014","unstructured":"Haddad, G. et al. Phosphoinositide 3-kinase \u03b2 mediates microvascular endothelial repair of thrombotic microangiopathy. Blood 124, 2142\u20132149 (2014).","journal-title":"Blood"},{"key":"36891_CR52","doi-asserted-by":"publisher","first-page":"e40589","DOI":"10.1371\/journal.pone.0040589","volume":"7","author":"D Veron","year":"2012","unstructured":"Veron, D. et al. Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphaVbeta3 integrin signaling in the glomerulus. PLoS ONE 7, e40589 (2012).","journal-title":"PLoS ONE"},{"issue":"6","key":"36891_CR53","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00467-017-3615-6","volume":"32","author":"MH Vaisbich","year":"2017","unstructured":"Vaisbich, M. H. et al. Thrombotic microangiopathy caused by methionine synthase deficiency: Diagnosis and treatment pitfalls. Pediatr. Nephrol. 32(6), 1089\u20131092 (2017).","journal-title":"Pediatr. Nephrol."},{"key":"36891_CR54","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/bs.vh.2022.01.002","volume":"119","author":"H Goubran","year":"2022","unstructured":"Goubran, H., Ragab, G. & Sabry, W. Metabolism-mediated thrombotic microangiopathy and B12. Vitam. Horm. 119, 441\u2013455 (2022).","journal-title":"Vitam. Horm."},{"issue":"3","key":"36891_CR55","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1055\/s-2000-8469","volume":"26","author":"A Coppola","year":"2000","unstructured":"Coppola, A. et al. Homocysteine, coagulation, platelet function, and thrombosis. Semin. Thromb. Hemost. 26(3), 243\u2013254 (2000).","journal-title":"Semin. Thromb. Hemost."},{"issue":"1","key":"36891_CR56","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/17843286.2019.1649039","volume":"76","author":"J Bernards","year":"2021","unstructured":"Bernards, J. et al. Hyperhomocysteinemia: A trigger for complement-mediated TMA? Acta Clin. Belg. 76(1), 65\u201369 (2021).","journal-title":"Acta Clin. Belg."},{"key":"36891_CR57","unstructured":"F. Hoffmann-La Roche Ltd. Emicizumab Global Medical Information Site. https:\/\/www.emicizumabinfo.global\/en\/homepage.html (Accessed June 2023)."},{"key":"36891_CR58","unstructured":"Lee, L. et al. Summary of thromboembolic (TE) or thrombotic microangiopathy (TMA) events in persons taking emicizumab. Presented at NHF 2020, August 1\u20138. Virtual. https:\/\/www.emicizumabinfo.com\/content\/dam\/gene\/emicizumabinfo\/pdf\/presentations\/nhf-2020-poster-lee-summary-of-thromboembolic-or-thrombotic-microangiopathy-events-in-persons-with-hem.pdf (Accessed January 2023)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36891-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36891-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36891-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T10:07:28Z","timestamp":1687342048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-36891-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["36891"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-36891-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"3 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RV was full-time employee at Anaxomics Biotech at the time of the study, and MC, and LA are full time employees at Anaxomics Biotech. JW, GM, and CS were full time employees at F. Hoffmann-La Roche Ltd at the time of the study. IPP was a full-time employee at Genentech, Inc. at the time of the study. GJ was a full-time employee at Iridessa SA at the time of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10078"}}